Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Advanced Endometrial Cancer (PANDA)
NCT02127151Phase 2Withdrawn
- Sponsor
- University College London
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in endometrial cancer (EC), sponsored by University College London. Primary endpoint: Progression Free Survival Rate at 6 months. Planned start Oct 2014; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02127151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127151.